ARTICLE | Clinical News
Therion Phase I data
May 11, 2000 7:00 AM UTC
Therion Biologics ( Cambridge, Mass.) and colleagues published in Clinical Cancer Research data from a 33-patient Phase I study of the company's Prostvac vaccine to treat advanced prostate cancer. Treatment with Prostvac gave PSA stabilization lasting at least six months in 14 patients, and lasting 11-25 months in 9 patients. Stable PSA levels were correlated with an absence of other indications of disease progression, Therion said. ...